Abstract:Background . Hedgehog (Hh) signaling is essential for osteoblast differentiation of mesenchymal progenitors during endochondral bone formation. However, the critical role of Hh signaling during adult bone remodeling remains to be elucidated. Methods . A Smoothened (SMO) antagonist/Hedgehog inhibitor, BMS-833923, identified during a functional screening of a stem cell signaling small molecule library, was investigated for its effects on the osteoblast differentiation of human skeletal (mesenchymal) stem cells (hMSC). Alkaline phosphatase (ALP) activity and Alizarin red staining were employed as markers for osteoblast differentiation and in vitro mineralization capacity, respectively. Global gene expression profiling was performed using the Agilent® microarray platform. Effects on in vivo ectopic bone formation were assessed by implanting hMSC mixed with hydroxyapatite-tricalcium phosphate granules subcutaneously in 8-week-old female nude mice, and the amount of bone formed was assessed using quantitative histology. Results . BMS-833923, a SMO antagonist/Hedgehog inhibitor, exhibited significant inhibitory effects on osteoblast differentiation of hMSCs reflected by decreased ALP activity, in vitro mineralization, and downregulation of osteoblast-related gene expression. Similarly, we observed decreased in vivo ectopic bone formation. Global gene expression profiling of BMS-833923-treated compared to vehicle-treated control cells, identified 348 upregulated and 540 downregulated genes with significant effects on multiple signaling pathways, including GPCR, endochondral ossification, RANK-RANKL, insulin, TNF alpha, IL6, and inflammatory response. Further bioinformatic analysis employing Ingenuity Pathway Analysis revealed significant enrichment in BMS-833923-treated cells for a number of functional categories and networks involved in connective and skeletal tissue development and disorders, e.g., NF κ B and STAT signaling. Conclusions . We identified SMO/Hedgehog antagonist (BMS-833923) as a powerful inhibitor of osteoblastic differentiation of hMSC that may be useful as a therapeutic option for treating conditions associated with high heterotopic bone formation and mineralization.

Purmorphamine Induces Osteogenesis by Activation of the Hedgehog Signaling Pathway.

A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells.

A Novel Piezo1 Agonist Promoting Mesenchymal Stem Cell Proliferation and Osteogenesis to Attenuate Disuse Osteoporosis

Effect of Purmorphamine on Neural Stem Cell Differentiation and Its Mechanism

Higenamine Promotes Osteogenesis via IQGAP1/SMAD4 Signaling Pathway and Prevents Age‐ and Estrogen‐Dependent Bone Loss in Mice

Mollugin enhances the osteogenic action of BMP-2 via the p38–Smad signaling pathway

Directed Transdifferentiation of Müller Glial Cells to Photoreceptors Using the Sonic Hedgehog Signaling Pathway Agonist Purmorphamine.

Selective Small Molecule Compounds Increase BMP-2 Responsiveness by Inhibiting Smurf1-mediated Smad1/5 Degradation

Hedgehog Signaling Inhibition by Smoothened Antagonist BMS-833923 Reduces Osteoblast Differentiation and Ectopic Bone Formation of Human Skeletal (Mesenchymal) Stem Cells

Osteomodulin positively regulates osteogenesis through interaction with BMP2

Synthetic Osteogenic Growth Peptide Promotes Differentiation of Human Bone Marrow Mesenchymal Stem Cells to Osteoblasts Via RhoA/ROCK Pathway.

Purmorphamine as a Shh Signaling Activator Small Molecule Promotes Motor Neuron Differentiation of Mesenchymal Stem Cells Cultured on Nanofibrous PCL Scaffold

Effect of osteogenic growth peptide on gene expression changes in bone mesenchymal stem cells of OPG~(-/-) mice:A Microarray analysis

Novel Hedgehog Agonists Promote Osteoblast Differentiation in Mesenchymal Stem Cells

Dimethyloxaloylglycine Promotes the Angiogenic Activity of Mesenchymal Stem Cells Derived from iPSCs via Activation of the PI3K/Akt Pathway for Bone Regeneration

Functional and Transcriptomic Analysis of the Regulation of Osteoblasts by Mechano‐growth Factor E Peptide

Harmine targets inhibitor of DNA binding‐2 and activator protein‐1 to promote preosteoclast PDGF‐BB production

A Novel Osteogenic Oxysterol Compound for Therapeutic Development to Promote Bone Growth: Activation of Hedgehog Signaling and Osteogenesis Through Smoothened Binding

Small-molecule modulators of the Sonic Hedgehog signaling pathway

Maohuoside A Acts in A Bmp-Dependent Manner During Osteogenesis

In vitro and in vivo studies on exogenous polyamines and α-difluoromethylornithine to enhance bone formation and suppress osteoclast differentiation